Anidulafungin PK in Infants and Toddlers

This study has been completed.
Information provided by (Responsible Party):
Michael Cohen-Wolkowiez, Duke University Medical Center Identifier:
First received: August 13, 2008
Last updated: November 16, 2012
Last verified: November 2012

This is a prospective, open-label, single center, pharmacokinetic study of anidulafungin in infants and toddlers less than 24 months of age with suspected serious infection. There will be up to 24 subjects enrolled; each will receive anidulafungin. Patients will receive anidulafungin 3 mg/kg loading dose on day 1 of study and will receive 1.5 mg/kg every 24 hours on study days 2-5.Plasma pharmacokinetics will be evaluated using a limited sampling scheme. We hypothesize that the PK parameters of anidulafungin will not differ from those observed in older children and adults.

Condition Intervention Phase
Invasive Fungal Infections
Drug: Anidulafungin
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Anidulafungin PK in Infants and Toddlers

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • The Pharmacokinetics (Area Under the Curve) of Anidulafungin in Infants and Toddlers Less Than 24 Months of Age With Suspected Serious Infection. [ Time Frame: 5 days ] [ Designated as safety issue: No ]
    Area under the curve at steady state

Secondary Outcome Measures:
  • Safety (Participants With Adverse Events) of Anidulafungin in Infants and Toddlers Less Than 24 Months of Age With Suspected Serious Infection. [ Time Frame: During and up to 10 days after last dose of study drug. ] [ Designated as safety issue: Yes ]
    Participants with Adverse events were collected during the study drug administration phase up to 10 days after last dose of study drug.

Enrollment: 15
Study Start Date: January 2008
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Drug: Anidulafungin
Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
Other Name: Eraxis


Ages Eligible for Study:   up to 24 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age < 24 months at the time of enrollment
  • Patient must have sufficient venous access to permit administration of study medication
  • Infant or toddler suspected to have a serious infection and from whom a blood culture has been obtained with 48 hours of study entry
  • Availability and willingness of the parent/legally authorized representative to provide written informed consent.

Exclusion Criteria:

  • Patients with a history of anaphylaxis attributed to an echinocandin
  • Any other concomitant condition, which in the opinion of the investigator would preclude a patient's participation in the study
  • Previous participation in this study
  • Previous exposure to an echinocandin in the month prior to study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00734500

United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Michael Cohen-Wolkowiez
  More Information

No publications provided

Responsible Party: Michael Cohen-Wolkowiez, Assistant Professor, Department of Pediatrics, Duke University Medical Center Identifier: NCT00734500     History of Changes
Other Study ID Numbers: Pro00000637
Study First Received: August 13, 2008
Results First Received: August 31, 2011
Last Updated: November 16, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Anti-Infective Agents
Antifungal Agents
Pharmacologic Actions
Therapeutic Uses processed this record on October 07, 2015